https://www.tipranks.com/news/the-fly/springworks-therapeutics-price-target-lowered-to-55-from-58-at-bofa BTIG analyst Julian Harrison initiated coverage of Avalo ...

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

As of December 3, 2024, the average one-year price target for Avalo Therapeutics is $35.70/share. The forecasts range from a low of $35.35 to a high of $36.75. The average price target represents ...

Avalo Therapeutics (AVTX), a clinical-stage biotechnology company, is taking steps to treat immune dysregulation. The company’s lead asset, AVTX-009, is a monoclonal antibody that targets ...

WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation ...